<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:d4cac778-6cfd-420c-a516-cd5560fabf80,g:a547a4e6-5f7b-4214-b491-f84955906741-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.madrigalpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mdgl-20240630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.madrigalpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_323da1ad-817e-4c71-9e96-6ed94b3e6ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_096df600-2f6f-4c88-b772-3d07a076c6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_323da1ad-817e-4c71-9e96-6ed94b3e6ec8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_096df600-2f6f-4c88-b772-3d07a076c6a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_734bb8b0-ab3e-4746-b88e-dc828babb811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_323da1ad-817e-4c71-9e96-6ed94b3e6ec8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_734bb8b0-ab3e-4746-b88e-dc828babb811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2453ea91-e52a-4862-a0f0-76605f53b3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1d03e787-d104-4730-b7aa-3bab4d4c4f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2453ea91-e52a-4862-a0f0-76605f53b3e4" xlink:to="loc_us-gaap_CommonStockValue_1d03e787-d104-4730-b7aa-3bab4d4c4f8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bf7ae6bb-aa5d-42c6-8226-b1cbea386eba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2453ea91-e52a-4862-a0f0-76605f53b3e4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bf7ae6bb-aa5d-42c6-8226-b1cbea386eba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f16a71c0-bddb-4e62-966f-502f966b4c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2453ea91-e52a-4862-a0f0-76605f53b3e4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f16a71c0-bddb-4e62-966f-502f966b4c2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c6eb94d4-6ddd-43ef-b339-45c8b5a1264b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2453ea91-e52a-4862-a0f0-76605f53b3e4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c6eb94d4-6ddd-43ef-b339-45c8b5a1264b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_53a253bb-4b86-4860-8306-5da0c57e904a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2453ea91-e52a-4862-a0f0-76605f53b3e4" xlink:to="loc_us-gaap_PreferredStockValue_53a253bb-4b86-4860-8306-5da0c57e904a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ad35ef7b-c25d-4887-a323-29fb7469a117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_28100882-4a82-433a-83cf-a16104469807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ad35ef7b-c25d-4887-a323-29fb7469a117" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_28100882-4a82-433a-83cf-a16104469807" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_043f1025-8059-4068-8f10-3287693d73cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ad35ef7b-c25d-4887-a323-29fb7469a117" xlink:to="loc_us-gaap_LiabilitiesCurrent_043f1025-8059-4068-8f10-3287693d73cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d5fe2a93-ad8c-4331-bae6-045d1ab6f6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b1eb1aca-e53d-4681-b68f-df19c279be6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d5fe2a93-ad8c-4331-bae6-045d1ab6f6c9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b1eb1aca-e53d-4681-b68f-df19c279be6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_bdd84bdb-da09-4299-8676-7d1eea9fc8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d5fe2a93-ad8c-4331-bae6-045d1ab6f6c9" xlink:to="loc_us-gaap_RestrictedCash_bdd84bdb-da09-4299-8676-7d1eea9fc8d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f0deced5-ee0e-4bd2-b825-f123ce4bb111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d5fe2a93-ad8c-4331-bae6-045d1ab6f6c9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f0deced5-ee0e-4bd2-b825-f123ce4bb111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bc434f69-2c59-4916-888f-94d808d1f51e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d5fe2a93-ad8c-4331-bae6-045d1ab6f6c9" xlink:to="loc_us-gaap_InventoryNet_bc434f69-2c59-4916-888f-94d808d1f51e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d08cf000-5c3a-4d82-92de-d3b200112922" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d5fe2a93-ad8c-4331-bae6-045d1ab6f6c9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d08cf000-5c3a-4d82-92de-d3b200112922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f0f49878-49a8-411f-ba5a-1d5fa678c369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d5fe2a93-ad8c-4331-bae6-045d1ab6f6c9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f0f49878-49a8-411f-ba5a-1d5fa678c369" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cc4784a7-37a3-4500-bef0-ce4b07f69e57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1a494e8a-02ff-48ee-aefb-444ce2ba39ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cc4784a7-37a3-4500-bef0-ce4b07f69e57" xlink:to="loc_us-gaap_StockholdersEquity_1a494e8a-02ff-48ee-aefb-444ce2ba39ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3dfada52-3ece-4324-9059-9ee0a2de07c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cc4784a7-37a3-4500-bef0-ce4b07f69e57" xlink:to="loc_us-gaap_Liabilities_3dfada52-3ece-4324-9059-9ee0a2de07c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_79a27166-2bcd-40e2-97d3-b3f970600ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_38e4be38-ecc1-4756-b4c7-809b3ec5e397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79a27166-2bcd-40e2-97d3-b3f970600ec4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_38e4be38-ecc1-4756-b4c7-809b3ec5e397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4190e6d2-e28e-4c7d-a25e-ea8f310d3d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79a27166-2bcd-40e2-97d3-b3f970600ec4" xlink:to="loc_us-gaap_AccountsPayableCurrent_4190e6d2-e28e-4c7d-a25e-ea8f310d3d25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_03c7eaf9-bf24-4588-969a-7d650026fdef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79a27166-2bcd-40e2-97d3-b3f970600ec4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_03c7eaf9-bf24-4588-969a-7d650026fdef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_352e98d3-e3aa-4821-9f48-6b774d87d69e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_143f2bc1-f9f7-47f0-b788-84c371176c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_352e98d3-e3aa-4821-9f48-6b774d87d69e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_143f2bc1-f9f7-47f0-b788-84c371176c66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a93e6e4d-20b6-4493-84c2-99c1108fa570" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_352e98d3-e3aa-4821-9f48-6b774d87d69e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a93e6e4d-20b6-4493-84c2-99c1108fa570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b7a04312-a3ad-4ecd-bcc5-350f7c6af2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_352e98d3-e3aa-4821-9f48-6b774d87d69e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b7a04312-a3ad-4ecd-bcc5-350f7c6af2d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5479fec6-1449-4547-8424-412d36039261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_352e98d3-e3aa-4821-9f48-6b774d87d69e" xlink:to="loc_us-gaap_AssetsCurrent_5479fec6-1449-4547-8424-412d36039261" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.madrigalpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mdgl-20240630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.madrigalpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d795da08-e2f0-4364-b5b2-f6ec2a36961e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_cfd63d1b-cb5b-4676-804c-bb4527701839" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d795da08-e2f0-4364-b5b2-f6ec2a36961e" xlink:to="loc_us-gaap_InterestExpense_cfd63d1b-cb5b-4676-804c-bb4527701839" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_bbe62661-a860-4d21-86dc-df7fce7fe151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d795da08-e2f0-4364-b5b2-f6ec2a36961e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_bbe62661-a860-4d21-86dc-df7fce7fe151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_afee84df-bb21-4a93-80bf-9af9c4866213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d795da08-e2f0-4364-b5b2-f6ec2a36961e" xlink:to="loc_us-gaap_OperatingIncomeLoss_afee84df-bb21-4a93-80bf-9af9c4866213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_05788299-41f7-43f3-80ff-215c799f8f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0acf80c8-53aa-4907-a5b0-f5a6dbe3f5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_05788299-41f7-43f3-80ff-215c799f8f1d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0acf80c8-53aa-4907-a5b0-f5a6dbe3f5f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f7d03f51-ba34-4403-8be6-27c35d160513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_05788299-41f7-43f3-80ff-215c799f8f1d" xlink:to="loc_us-gaap_OperatingExpenses_f7d03f51-ba34-4403-8be6-27c35d160513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_05ce24ed-3a83-4b2c-8860-384ba43ebc99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_d1cc3a6d-0d45-4b0f-a961-fbd6276838b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_05ce24ed-3a83-4b2c-8860-384ba43ebc99" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_d1cc3a6d-0d45-4b0f-a961-fbd6276838b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0861b83d-b809-4bf2-b097-55968ef572d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_05ce24ed-3a83-4b2c-8860-384ba43ebc99" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0861b83d-b809-4bf2-b097-55968ef572d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_50a176e8-a577-434a-9725-29981a1f4996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_05ce24ed-3a83-4b2c-8860-384ba43ebc99" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_50a176e8-a577-434a-9725-29981a1f4996" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.madrigalpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mdgl-20240630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.madrigalpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_92d2035e-84f7-4338-9f9f-df3da61863ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1d3c2830-cbe1-4ffe-8444-54d94afbd90e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_92d2035e-84f7-4338-9f9f-df3da61863ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1d3c2830-cbe1-4ffe-8444-54d94afbd90e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3842d0a7-6465-43a1-bd26-75dc6de7736e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_92d2035e-84f7-4338-9f9f-df3da61863ca" xlink:to="loc_us-gaap_NetIncomeLoss_3842d0a7-6465-43a1-bd26-75dc6de7736e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.madrigalpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mdgl-20240630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.madrigalpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_730f8078-3fcf-44f0-aa23-247a5105eccf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_b7fd3df7-d487-4472-8638-b958e7c4d725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_730f8078-3fcf-44f0-aa23-247a5105eccf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_b7fd3df7-d487-4472-8638-b958e7c4d725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromBankDebt_d86f6e7a-a191-40ee-b9b4-d9c6568e267b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromBankDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_730f8078-3fcf-44f0-aa23-247a5105eccf" xlink:to="loc_us-gaap_ProceedsFromBankDebt_d86f6e7a-a191-40ee-b9b4-d9c6568e267b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_15637c54-5581-469a-a48c-dd589fa64179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_730f8078-3fcf-44f0-aa23-247a5105eccf" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_15637c54-5581-469a-a48c-dd589fa64179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff4036f0-a709-416f-805e-874f62330f84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_e168c6ca-2a2b-4221-89dd-3ab44c44b151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff4036f0-a709-416f-805e-874f62330f84" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_e168c6ca-2a2b-4221-89dd-3ab44c44b151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2742e447-eefb-4340-ba0e-a75c68008d05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff4036f0-a709-416f-805e-874f62330f84" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2742e447-eefb-4340-ba0e-a75c68008d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdgl_IncreaseDecreaseInAccruedInterestNetOfInterestReceived_90405a0b-156d-4f7a-af72-98ea922ef39c" xlink:href="mdgl-20240630.xsd#mdgl_IncreaseDecreaseInAccruedInterestNetOfInterestReceived"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff4036f0-a709-416f-805e-874f62330f84" xlink:to="loc_mdgl_IncreaseDecreaseInAccruedInterestNetOfInterestReceived_90405a0b-156d-4f7a-af72-98ea922ef39c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ed481733-4e8a-48ef-9389-9b2cbb0eef33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff4036f0-a709-416f-805e-874f62330f84" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ed481733-4e8a-48ef-9389-9b2cbb0eef33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_89d7ac18-4b4b-444f-98a3-a72ade186073" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff4036f0-a709-416f-805e-874f62330f84" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_89d7ac18-4b4b-444f-98a3-a72ade186073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a46750eb-98ac-4090-b1d2-491856157253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff4036f0-a709-416f-805e-874f62330f84" xlink:to="loc_us-gaap_ProfitLoss_a46750eb-98ac-4090-b1d2-491856157253" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9c3edc44-0b1a-43ba-8f6c-90bf277fa4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff4036f0-a709-416f-805e-874f62330f84" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9c3edc44-0b1a-43ba-8f6c-90bf277fa4f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0c3f63da-63dd-4e98-8ad1-7b5e72ad131b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff4036f0-a709-416f-805e-874f62330f84" xlink:to="loc_us-gaap_ShareBasedCompensation_0c3f63da-63dd-4e98-8ad1-7b5e72ad131b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c1b36cec-aedd-4572-be4a-e37d71d5326d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff4036f0-a709-416f-805e-874f62330f84" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c1b36cec-aedd-4572-be4a-e37d71d5326d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ca195b42-e01b-4930-b8b7-efee91381a85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff4036f0-a709-416f-805e-874f62330f84" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ca195b42-e01b-4930-b8b7-efee91381a85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d80fe120-3bcf-458b-b925-b79f6bd6f4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b875ced4-a747-4f86-bc6b-f1dfb659b5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d80fe120-3bcf-458b-b925-b79f6bd6f4ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b875ced4-a747-4f86-bc6b-f1dfb659b5a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e867214-92d2-4a5c-9823-73f1630ddb12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d80fe120-3bcf-458b-b925-b79f6bd6f4ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e867214-92d2-4a5c-9823-73f1630ddb12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b69d3d7a-efbc-4514-a1c8-63181d3c123b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d80fe120-3bcf-458b-b925-b79f6bd6f4ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b69d3d7a-efbc-4514-a1c8-63181d3c123b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c9056f3c-75f8-463f-bf38-1fcfdfab28cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_6e0f8911-a8fd-4089-b46e-478c27747406" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c9056f3c-75f8-463f-bf38-1fcfdfab28cd" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_6e0f8911-a8fd-4089-b46e-478c27747406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ed97c91d-67ce-41f4-909b-1122fab7503b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c9056f3c-75f8-463f-bf38-1fcfdfab28cd" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ed97c91d-67ce-41f4-909b-1122fab7503b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_faaaf60f-5e12-438f-a694-a54f0fc44941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c9056f3c-75f8-463f-bf38-1fcfdfab28cd" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_faaaf60f-5e12-438f-a694-a54f0fc44941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30375b50-24ab-41fb-b7ca-fbfe5039be26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c9056f3c-75f8-463f-bf38-1fcfdfab28cd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30375b50-24ab-41fb-b7ca-fbfe5039be26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.madrigalpharma.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofcashcashequivalentsandavailableforsalemarketablesecuritiesDetails" xlink:type="simple" xlink:href="mdgl-20240630.xsd#CashCashEquivalentsandMarketableSecuritiesScheduleofcashcashequivalentsandavailableforsalemarketablesecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.madrigalpharma.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofcashcashequivalentsandavailableforsalemarketablesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a4f51864-e078-4cd3-a8d5-7adea24ef85c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aec931ce-0705-46b4-8304-3cd9be2d7fce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a4f51864-e078-4cd3-a8d5-7adea24ef85c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aec931ce-0705-46b4-8304-3cd9be2d7fce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f86e33ed-60f2-4cca-82f3-95aba69a9d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a4f51864-e078-4cd3-a8d5-7adea24ef85c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f86e33ed-60f2-4cca-82f3-95aba69a9d49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_30868deb-8311-4c03-b044-7b3f6c6c65b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a4f51864-e078-4cd3-a8d5-7adea24ef85c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_30868deb-8311-4c03-b044-7b3f6c6c65b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdgl_CashCashEquivalentsAndShortTermInvestmentsAtCost_272dc4a6-98d3-4f4e-ab40-b9cf5e1c436b" xlink:href="mdgl-20240630.xsd#mdgl_CashCashEquivalentsAndShortTermInvestmentsAtCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_938c33ec-4790-4af6-a65c-21253edd662e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdgl_CashCashEquivalentsAndShortTermInvestmentsAtCost_272dc4a6-98d3-4f4e-ab40-b9cf5e1c436b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_938c33ec-4790-4af6-a65c-21253edd662e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_8c1b91e9-a788-4f28-b1f5-1d548ed47d61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdgl_CashCashEquivalentsAndShortTermInvestmentsAtCost_272dc4a6-98d3-4f4e-ab40-b9cf5e1c436b" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_8c1b91e9-a788-4f28-b1f5-1d548ed47d61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_651eb96f-4761-43bf-9fa1-9ee4e3cbade3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdgl_CashCashEquivalentsAndShortTermInvestmentsAtCost_272dc4a6-98d3-4f4e-ab40-b9cf5e1c436b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_651eb96f-4761-43bf-9fa1-9ee4e3cbade3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.madrigalpharma.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofcashcashequivalentsandavailableforsalemarketablesecuritiesDetails_1" xlink:type="simple" xlink:href="mdgl-20240630.xsd#CashCashEquivalentsandMarketableSecuritiesScheduleofcashcashequivalentsandavailableforsalemarketablesecuritiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.madrigalpharma.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofcashcashequivalentsandavailableforsalemarketablesecuritiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mdgl_CashCashEquivalentsAndShortTermInvestmentsAtCost_71ac68cd-7522-4088-ba7b-02fc8bf2de90" xlink:href="mdgl-20240630.xsd#mdgl_CashCashEquivalentsAndShortTermInvestmentsAtCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f35300d6-f332-4b8c-838e-a07092204341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdgl_CashCashEquivalentsAndShortTermInvestmentsAtCost_71ac68cd-7522-4088-ba7b-02fc8bf2de90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f35300d6-f332-4b8c-838e-a07092204341" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d0382a15-b8e7-4370-b204-d7bab4dc1322" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdgl_CashCashEquivalentsAndShortTermInvestmentsAtCost_71ac68cd-7522-4088-ba7b-02fc8bf2de90" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d0382a15-b8e7-4370-b204-d7bab4dc1322" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.madrigalpharma.com/role/InventoryDetails" xlink:type="simple" xlink:href="mdgl-20240630.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.madrigalpharma.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7870c571-08ca-45cb-a986-201efa107623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e82c0aa8-608c-45b7-9ee3-617eea4a84b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7870c571-08ca-45cb-a986-201efa107623" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e82c0aa8-608c-45b7-9ee3-617eea4a84b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_558bee2c-2eb2-4620-897f-e132715a888c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7870c571-08ca-45cb-a986-201efa107623" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_558bee2c-2eb2-4620-897f-e132715a888c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_49834d0e-3818-40d9-aa80-7dcbe63f57a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7870c571-08ca-45cb-a986-201efa107623" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_49834d0e-3818-40d9-aa80-7dcbe63f57a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mdgl-20240630.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b8797613-2b72-4e1c-a800-656bf75aeb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_9b5796c0-675f-4328-9996-239e425334bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b8797613-2b72-4e1c-a800-656bf75aeb7a" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_9b5796c0-675f-4328-9996-239e425334bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdgl_AccruedExpensesGross_ea1a733a-71ec-4dd3-9c33-45f965274497" xlink:href="mdgl-20240630.xsd#mdgl_AccruedExpensesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b8797613-2b72-4e1c-a800-656bf75aeb7a" xlink:to="loc_mdgl_AccruedExpensesGross_ea1a733a-71ec-4dd3-9c33-45f965274497" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdgl_AccruedOtherClinicalStudyRelatedCostsCurrent_17db6278-de0c-4a8a-a9d8-48586d63db7b" xlink:href="mdgl-20240630.xsd#mdgl_AccruedOtherClinicalStudyRelatedCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b8797613-2b72-4e1c-a800-656bf75aeb7a" xlink:to="loc_mdgl_AccruedOtherClinicalStudyRelatedCostsCurrent_17db6278-de0c-4a8a-a9d8-48586d63db7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0728065e-7518-4fd9-a44e-6746b3cf4b91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b8797613-2b72-4e1c-a800-656bf75aeb7a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0728065e-7518-4fd9-a44e-6746b3cf4b91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ad64f8f7-641c-4011-9e82-721996ec3d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b8797613-2b72-4e1c-a800-656bf75aeb7a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ad64f8f7-641c-4011-9e82-721996ec3d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdgl_AccruedContractResearchCostsCurrent_600707c6-5fbd-4345-b14e-ad8211cf2042" xlink:href="mdgl-20240630.xsd#mdgl_AccruedContractResearchCostsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b8797613-2b72-4e1c-a800-656bf75aeb7a" xlink:to="loc_mdgl_AccruedContractResearchCostsCurrent_600707c6-5fbd-4345-b14e-ad8211cf2042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdgl_AccruedManufacturingAndDrugSupplyCurrent_006950eb-86b3-481e-99fd-260667d58c53" xlink:href="mdgl-20240630.xsd#mdgl_AccruedManufacturingAndDrugSupplyCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b8797613-2b72-4e1c-a800-656bf75aeb7a" xlink:to="loc_mdgl_AccruedManufacturingAndDrugSupplyCurrent_006950eb-86b3-481e-99fd-260667d58c53" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.madrigalpharma.com/role/LongTermDebtScheduleofMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="mdgl-20240630.xsd#LongTermDebtScheduleofMaturitiesofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.madrigalpharma.com/role/LongTermDebtScheduleofMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_42228a18-babd-4edc-a6da-db1592e43d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdgl_LongTermDebtMaturityAfterYearTwo_5f28cdbe-e771-4196-8eac-075934551002" xlink:href="mdgl-20240630.xsd#mdgl_LongTermDebtMaturityAfterYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_42228a18-babd-4edc-a6da-db1592e43d5e" xlink:to="loc_mdgl_LongTermDebtMaturityAfterYearTwo_5f28cdbe-e771-4196-8eac-075934551002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_30498ee4-4367-4c07-b529-ab90da513525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_42228a18-babd-4edc-a6da-db1592e43d5e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_30498ee4-4367-4c07-b529-ab90da513525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0ae21dda-64ad-4bfb-bbaa-bad6ad2d972e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_42228a18-babd-4edc-a6da-db1592e43d5e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0ae21dda-64ad-4bfb-bbaa-bad6ad2d972e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8ac746db-0697-466a-902b-d51c3612de02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_42228a18-babd-4edc-a6da-db1592e43d5e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8ac746db-0697-466a-902b-d51c3612de02" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
